Real‐world effects of beremagene geperpavec in epidermolysis bullosa
BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a severe inherited skin fragility disorder caused by mutations in COL7A1, leading to wounds, inflammation and impaired quality of life. Beremagene geperpavec (B-VEC) is the first approved topical gene therapy delivering functional COL7A1 via a modified HSV-1 vector, enabling local collagen VII expression and improved wound healing. OBJECTIVES: To evaluate the real-world, multidimensional long-term outcomes of B-VEC treatment in patients with DEB, including wound healing, systemic inflammation, (auto)-antibody profiles and patient-reported outcomes. METHODS: In this multicentre observational study, 38 patients with DEB received B-VEC treatment between January 2024 and June 2026. The primary endpoint was the change in wound surface area from baseline during B-VEC treatment. Secondary endpoints included changes in systemic inflammatory and haematological parameters [C-reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), leucocytes and haemoglobin (Hb)], (auto-)antibody profiles [anti-C7, BP180, BP230 and herpes simplex virus (HSV)-1/2 IgG], body mass index (BMI) and patient-reported outcomes, including pain, pruritus, treatment satisfaction and wound dressing time. RESULTS: B-VEC treatment was associated with a significant reduction in wound surface area across healing wounds. Patients having persistent wounds exhibited lower BMI and higher leucocyte counts and received systemic biologic therapies less frequently. Anti-BP180, BP230 and HSV-1/2 titres remained stable, while anti-C7 levels increased during treatment. IIF was negative in most patients and did not differ between groups. Systemic inflammation showed a mixed pattern, with reduced leucocyte counts and SAA levels, and slightly increased CRP and IL-6 under treatment. Hb and BMI increased during treatment. Most patients reported high treatment satisfaction and reduction in pain, pruritus and wound dressing time. CONCLUSIONS: B-VEC therapy provides clinically meaningful improvements in wound healing, patient-reported outcomes and selected systemic parameters in DEB. Treatment response is influenced by host factors such as BMI, systemic inflammation and concomitant therapies. Baseline (auto)-antibody profiles do not appear to predict treatment efficacy. Overall, B-VEC represents a significant advancement in the multidimensional management of DEB in real-world clinical practice.
Authors
- Robin Frank (ORCID: https://orcid.org/0000-0001-6045-2306)
- Meropi Karakioulaki (ORCID: https://orcid.org/0000-0002-1067-8582)
- Stella Gewert (ORCID: https://orcid.org/0000-0002-7165-0938)
- Moritz Hess (ORCID: https://orcid.org/0000-0003-4021-1796)
- Hanning Yang (ORCID: https://orcid.org/0009-0004-0194-2291)
- Margret Pohl
- Oliver Storz
- Miodrag Davidovic
- Cristina Has (ORCID: https://orcid.org/0000-0001-6066-507X)
- Kilian Eyerich (ORCID: https://orcid.org/0000-0003-0094-2674)
- Anna Luisa Hartmann
- Nikolaos Stavropoulos (ORCID: https://orcid.org/0009-0001-4093-1200)
- Nora Hummel
Institutions
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- St. Josef-Hospital (DE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1111/jdv.70839
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00